Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Open-Label Study of PRA023 in Moderately to Severely Active Crohn's Disease
2021-000092-37Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tulisokibart in Crohn's disease, sponsored by Merck & Co. Primary endpoint: Safety and tolerability. Started Jun 2021; status: active.
02
Drugs
tulisokibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2021-000092-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000092-37.